Julia Foldi

Assistant Professor of Medicine

University of Pittsburgh School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Julia Foldi is an Assistant Professor of Medicine at the University of Pittsburgh School of Medicine in the United States. Her primary research areas focus on the immunological aspects of disease progression in children with perinatal human immunodeficiency virus. Recent articles by Dr. Foldi explore the correlation between disease progression and increased PD-1 + CD8 T cells that coexpress multiple immune checkpoints.

Articles (4)

PURPOSE We performed spatial transcriptomics of estrogen receptor (ER)–negative, ER-low, and ER-high tumor regions of breast cancers that were intermediate (10%-60%) ER-positive by immunohistochemistry to better understand the intratumor heterogeneity in ER expression and to elucidate whether cells of different molecular subtypes (ie, Luminal A [LumA], Luminal B [LumB], human epidermal growth factor receptor 2–enriched, or Basal-like) can coexist in the same tumor. METHODS Digital spatial profiling was performed on 10 ER-heterogeneous (10%-60% ER+) and 10 ER-high (>60% ER+) primary breast cancers using the NanoString GeoMx platform with the Human Whole Transcriptome Atlas probe set. RESULTS LumA and LumB molecular subtypes were intermixed, but there were no Basal-like populations in these ER-heterogeneous tumors. The ER-negative (ER–) regions were LumB-like and showed lower expression of ESR1 and endocrine therapy sensitivity gene signatures but higher expression of immune-related genes and higher recurrence scores, indicating a more endocrine-resistant but chemotherapy-sensitive phenotype. We also found that ESR1 strongly positive cells enriched after preoperative chemotherapy in clinical trial tissues. CONCLUSION This study demonstrates mixed Lum-A and Lum-B molecular subtypes within ER-intermediate primary breast cancers and reveals that ER– tumor cell populations have molecular features of endocrine resistance but chemotherapy sensitivity. These findings may explain the worse clinical outcomes of patients with ER-heterogeneous breast cancers and suggest benefit from combined endocrine and chemotherapy strategies.

Year:

2025

PURPOSE Despite varying treatment responses and vastly different clinicopathologic characteristics, invasive lobular carcinoma (ILC) is treated similar to other subtypes of breast cancer. Serial personalized and tumor-informed, circulating tumor DNA (ctDNA) analysis may enable real-time treatment monitoring in metastatic ILC (mILC). METHODS In this retrospective analysis of real-world data, we analyzed ctDNA longitudinally in 66 patients with mILC using a clinically validated, personalized, tumor-informed 16-plex polymerase chain reaction-next generation sequencing assay (Signatera). We evaluated the predictive value on survival of a single ctDNA test result and correlated ctDNA detection rates and on-treatment ctDNA dynamics with disease status. RESULTS A total of 355 plasma samples were analyzed from 66 patients with mILC (median age at diagnosis, 62.6 years [range, 32.2-79.7 years]). On treatment, ctDNA dynamics correlated well with clinical response to treatment as assessed by imaging. Ninety-two percent (11 of 12) of patients with either ctDNA decrease (6 of 6) or no change in ctDNA levels (5 of 6) while on treatment showed clinical benefit from their prescribed regimen, whereas only 31% (4 of 13) of patients who showed an increase in their ctDNA had a clinical benefit on imaging. Finally, patients with a positive ctDNA test showed a greater probability of death compared with those with negative results, and the positive predictive value of ctDNA testing continued to increase exponentially with each positive result. Similarly, a negative ctDNA result was associated with 97% overall survival at 6 months and remained high (approximately 90%) at the 12-month follow-up. CONCLUSION Serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring.

Year:

2025

Understanding interplay of breast cancer and microenvironment is critical. Here, we identified two transcriptomic subtypes and five immune infiltration patterns from RNA-seq and multiplex immunohistochemistry from 21 ER+/HER2- invasive lobular breast cancers. The proliferative subtype associated with increased immune infiltration especially by immunosuppressive regulatory T-cells and macrophages. We also defined a TAM-Low signature, which associated with lower infiltration of proliferative, pro-inflammatory TAM, and improved outcome in patients with ER+ tumors.

Year:

2024

Year:

2021

Collaborators (6)

George Tseng

Professor and Vice Chair for Research

University of Pittsburgh

UNITED STATES
View details

Lajos Pusztai

Yale University

UNITED STATES
View details

Adrian V. Lee

University of Pittsburgh

UNITED STATES
View details

Steffi Oesterreich

UPMC Hillman Cancer Center

UNITED STATES
View details

Minetta Liu

Research Collaborator, Professor

Mayo Clinic

UNITED STATES
View details

David Rimm

Professor

Yale University

UNITED STATES
View details